B
Braidwell Portfolio holdings
AUM
$2.92B
This Quarter Return
+2.55%
1 Year Return
-4.59%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$2.92B
AUM Growth
+$2.92B
(+2.8%)
Cap. Flow
+$71.1M
Cap. Flow
% of AUM
2.43%
Top 10 Holdings %
Top 10 Hldgs %
45.84%
Holding
71
New
6
Increased
13
Reduced
17
Closed
13
Top Buys
| 1 |
CAI
Caris Life Sciences, Inc. Common Stock
CAI
|
$195M |
| 2 |
Krystal Biotech
KRYS
|
$45M |
| 3 |
Edgewise Therapeutics
EWTX
|
$36.1M |
| 4 |
Inspire Medical Systems
INSP
|
$28.5M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$28M |
Top Sells
| 1 |
Transmedics
TMDX
|
$80.4M |
| 2 |
iRhythm Technologies
IRTC
|
$39.5M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$38.9M |
| 4 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$28.2M |
| 5 |
Guardant Health
GH
|
$25.5M |
Sector Composition
| 1 | Healthcare | 71.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CAI
1
Caris Life Sciences, Inc. Common Stock
CAI
$10.8B
| $195M | 6.69% | +7,316,142 | New | +$195M |
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $146M | 4.99% | 1,160,425 -31,500 | -3% | -$3.96M |
|
|
3
Xenon Pharmaceuticals
XENE
$2.98B
| $113M | 3.86% | 3,605,029 +895,154 | +33% | +$28M |
|
4
argenx
ARGX
$43.6B
| $107M | 3.67% | 194,491 +33,642 | +21% | +$18.5M |
|
|
5
Krystal Biotech
KRYS
$4.27B
| $100M | 3.42% | 727,811 +327,067 | +82% | +$45M |
|
6
Align Technology
ALGN
$10.3B
| $94M | 3.22% | 496,730 -33,800 | -6% | -$6.4M |
|
7
Legend Biotech
LEGN
$6.41B
| $90.2M | 3.09% | 2,542,104 -435,847 | -15% | -$15.5M |
|
8
Nuvalent
NUVL
$5.52B
| $89.7M | 3.07% | 1,175,876 +334,931 | +40% | +$25.6M |
|
9
CG Oncology
CGON
$2.04B
| $85.4M | 2.92% | 3,283,317 | – | – |
|
|
10
Edgewise Therapeutics
EWTX
$1.51B
| $68.3M | 2.34% | 5,210,831 +2,752,023 | +112% | +$36.1M |
|
|
11
Inspire Medical Systems
INSP
$2.77B
| $67.8M | 2.32% | 522,410 +220,000 | +73% | +$28.5M |
|
12
Apogee Therapeutics
APGE
$2.17B
| $64.2M | 2.2% | 1,478,512 -61,850 | -4% | -$2.69M |
|
13
Glaukos
GKOS
$5.5B
| $62.3M | 2.13% | 603,414 -21,021 | -3% | -$2.17M |
|
14
Danaher
DHR
$147B
| $61.1M | 2.09% | 309,339 | – | – |
|
15
Thermo Fisher Scientific
TMO
$186B
| $54.8M | 1.88% | 135,233 +7,500 | +6% | +$3.04M |
|
16
Intuitive Surgical
ISRG
$170B
| $48.7M | 1.67% | 89,600 +1,600 | +2% | +$869K |
|
|
17
iRhythm Technologies
IRTC
$5.46B
| $46.2M | 1.58% | 300,029 -256,362 | -46% | -$39.5M |
|
18
Adaptive Biotechnologies
ADPT
$2.01B
| $45M | 1.54% | 3,863,107 -940,687 | -20% | -$11M |
|
|
19
Guardant Health
GH
$8.41B
| $43.6M | 1.49% | 837,800 -489,527 | -37% | -$25.5M |
|
20
Alphatec Holdings
ATEC
$2.35B
| $40.4M | 1.38% | 3,635,172 -624,257 | -15% | -$6.93M |
|
21
Spyre Therapeutics
SYRE
$996M
| $38.6M | 1.32% | 2,578,404 | – | – |
|
22
Viking Therapeutics
VKTX
$3.04B
| $38.1M | 1.3% | 1,437,555 +1,600 | +0.1% | +$42.4K |
|
|
23
Transmedics
TMDX
$3.92B
| $34.2M | 1.17% | 255,048 -599,836 | -70% | -$80.4M |
|
24
Penumbra
PEN
$10.6B
| $33.3M | 1.14% | 129,628 +19,500 | +18% | +$5M |
|
25
Dyne Therapeutics
DYN
$1.92B
| $31.2M | 1.07% | 3,273,349 -347,995 | -10% | -$3.31M |
|